NCT01840501 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Healthy

Interventions

DRUG

JNJ-42721458 (single dose)

JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.

DRUG

JNJ-42721458 (multiple doses)

JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.

DRUG

Placebo (single dose)

Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.

DRUG

Placebo (multiple doses)

Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.

Trial Locations (1)

Merksem

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY